Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication
The purpose of this guideline is to provide physicians, nurses, pharmacists and other health care providers who care for children aged 1 month to 18 years who are receiving antineoplastic medication with an approach to the prevention of acute antineoplastic-induced nausea and vomiting (CINV). The scope of this guideline is limited to the prevention of AINV in the acute phase (within 24 hours of administration of an antineoplastic agent). Its scope does not include anticipatory, breakthrough or delayed phase CINV, or nausea and vomiting that is related to radiation therapy, disease, co-incident conditions or end-of-life care. Management of anticipatory, breakthrough and delayed AINV will be addressed in a future POGO guideline. This guideline is most applicable to children who are naïve to antineoplastic therapy and who are about to receive their first course of antineoplastic therapy.
This guideline represents the second in a series of guidelines to address the need for, and the selection of, antiemetic prophylaxis and intervention in children with cancer receiving antineoplastic therapy. These guidelines will lead to improvements in the supportive care of children with cancer by offering a standardized, evidence-based approach to the prophylaxis of CINV, optimization of CINV control and provision of cost-effective antiemetic prophylaxis.
View this guideline through open access published in Pediatric Blood and Cancer.
View a focused update of this guideline as an open access publication in Pediatric Blood and Cancer.
Click here to see the search strategy used for the update of this guideline.